Document is current
Any future updates will be listed below
-
Authors
Aslanis, Vassilios https://orcid.org/0000-0003-0997-0081
Abd-Elaziz, Khalid https://orcid.org/0000-0002-0964-4940
Slack, Robert J. https://orcid.org/0000-0002-4372-9438
Brinch, Anne
Gravelle, Lise
Morley, Wayne
Phung, De
Herman, Kimberly https://orcid.org/0000-0002-8672-0599
Holyer, Ian
Poulsen, Karen Killerup
Dogterom, Peter
Tantawi, Susan https://orcid.org/0009-0000-7671-0568
Zetterberg, Fredrik R. https://orcid.org/0000-0002-7789-8782
Jacoby, Brian
Schambye, Hans
Lindmark, Bertil
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05747573 at ClinicalTrials.govDocuments that mention this clinical trial
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)
https://doi.org/10.1007/s00280-024-04710-3
-
Funding
Funding for this research was provided by:
Galecto Biotech AB
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 10 August 2024
First Online: 21 August 2024
Declarations
:
: VA, RJS, LG, BJ, and HS are employees and hold stock or stock options (publicly traded company) at Galecto Biotech AB. KA-E is an employee of QPS-Netherlands, B.V. which received funding for the studies from Galecto Biotech AB. AB was an employee at Galecto Biotech AB during the time of the study, and is now an employee at Minervax ApS. WM was an employee, at the time of this study, and holds stock (privately held/publicly traded company [individual stocks]) at Galecto Biotech AB, and is now a consultant for Agomab. KH was an employee of and previously held stocks (publicly traded company [individual stocks and stock options]) at Galecto Biotech AB, at the time of this study, and is now an employee of Sitryx. IH and FZ were employees and previously held stocks (publicly traded company [individual stocks and stock options]) at Galecto Biotech AB, at the time of this study. KKP is an employee at and holds stock or stock options (publicly traded company [excluding mutual/index funds or pension plans]) at Galecto Biotech AB. PD has nothing to disclose. ST was an employee, at the time of this study, and holds stock (publicly traded company [individual stocks and stock options]) at Galecto Biotech AB and is now an independent consultant at Akcella Consulting Firm Inc. BL was an employee, at the time of this study, and holds stock or stock options (publicly traded company) at Galecto Biotech AB and is now an employee at Vicore Pharma.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the current version of the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice, and the local regulation in the Netherlands (WHO). The study was approved by the Medical Research Ethics Committee Foundation for the Assessment of Ethics for Biomedical Research (BEBO) in Assen on December 20, 2022. The study was approved under the Regulation (EU) No. 536/2014. Participant consent Informed consent was obtained from all individual participants included in the study, prior to any study-related activity.
